Skip to main content
. Author manuscript; available in PMC: 2015 May 18.
Published in final edited form as: Pharmacogenet Genomics. 2012 Sep;22(9):653–658. doi: 10.1097/FPC.0b013e3283562d82

Table 2.

TXAS kinetic parameters for purified wild-type and variant proteinsa.

wild-type K258E L357V Q417E E450K T451N
KM, µM PGH2 32.0 ± 2.7 51.9 ± 4.3
(p= 0.017)b
51.0 ± 2.5
(p= 0.007)
27.1 ± 3.6
(p> 0.05)
33.8 ± 2.4
(p> 0.05)
46.7 ± 3.9
(p= 0.036)
Vmax, units /mg
protein
40.8 ± 1.0 32.9 ± 1.0
(p= 0.005)
18.1 ± 1.0
(p= 0.0001)
39.7 ± 1.0
(p> 0.05)
32.9 ± 1.0
(p= 0.005)
34.0 ± 1.0
(p= 0.009)
Vmax /KM,
units/mg/µM
PGH2
1.28 ± 0.14 0.64 ± 0.07
(p= 0.015)
0.35 ± 0.04
(p=0.0031)
1.46 ± 0.23
(p> 0.05)
0.97 ± 0.10
(p> 0.05)
0.72 ± 0.08
(p= 0.025)
a

Activity was assayed by following the absorbance changes at 268 nm for MDA formation in the presence of 5 nM TXAS. Values represent mean ± SEM of three experiments.

b

p-values are calculated as compared to the wild-type, and values larger than 0.05 are considered to be statistically in-significant.